Matricelf Ltd.

Investor Presentation • Mar 27, 2024

REGENERATING THE FUTURE OF MEDICINE

Forward Looking Statement and Disclosure

This presentation was prepared by Matricelf Ltd. (The "Company"), as a general introductory presentation. As such, the information it includes is non-exhaustive and does not cover all the information about the Company and its operations. Therefore, this presentation is not intended to replace any need to review the Company's reports as published from time to time, including any supplementary prospectus of the Company. The information included in this presentation does not purport to survey or include all the information that could be relevant for the purpose of reaching any conclusion related to investment in the securities of the Company. The Company is also not obligated to update or change the information included in this presentation so that it reflects events, additional editing, processing, or segmentation that may differ from the current depiction in this presentation or any change that may take place after the date of its preparation. This presentation includes forward-looking information, as defined in the Securities Law 1968 including outlooks, evaluations, estimates, and other information related to the events and matters that will take place or may take place in the future, including with regard to the outlook on income and profitability, whose occurrence is not certain and is not under the exclusive control of the Company. Forward-looking statements in the presentation are based on estimates and assumptions of the management of the Company as of the date of preparation of the presentation, which are uncertain by their nature, due to their dependence on the risks inherent in the Company's operations, and which are not under the Company's control, each of which, or a combination thereof, is liable to negatively impact the results of the Company and, consequentially, the realization of these estimates and outlooks. The presentation includes statistical data and published information that were published by third parties, the content of which was not verified by the Company, and the Company is not responsible for their validity. The information included in the presentation does not constitute a proposal or invitation to make an offer to purchase the Company's securities.

Unique regenerative medicine company specializing in tissue engineering utilizing autologous cells & tissues Extensive IP - 6 patent families

Two platform technologies

• ✓ Generation of autologous engineered tissues
• ✓ Volumetric 3D bioprinting

First product in development

• ✓ Autologous engineered neural tissue to repair paralysis
• ✓ Unique solution for spinal cord injury, a major unmet medical need

• ✓ Two issued patents*
• ✓ Active prosecution of the portfolio

Vision

Revolutionizing the future of personalized therapies to solve critical unmet medical conditions and to improve patient's quality of life

Engineered tissue Generation of autologous 3D-engineered tissues

utilizing the patient's own induced Pluripotent Stem Cells and Extracellular Matrix

Generation of complex and volumetric tissues

utilizing 3D bioprinting techniques*

* Early development stage

Intellectual property Status

Extensive IP, comprising 6 patent families, which cover the compositions and methods of manufacture relevant to the company's therapeutic modality and the use of the modality in specific indications.

Two issued patents Active prosecution of the portfolio

First Indication: Traumatic spinal cord injury

Every day, ~700* individuals worldwide injure their spinal cords, resulting in varying levels of paralysis.

Matricelf aspires to rectify this devastating condition by restoring the "missing piece" in the damaged spinal cord.

* World Health Organization (WHO): https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury

Humanity has succeeded in reaching space, but we still haven't managed to bridge the two centimeters of an injured spinal cord Humanity has succeeded in reaching space, but we still haven't managed to bridge the

Yariv Bash, Co-founder, SpaceIL

Spinal Cord Injury – the metrics

USA*

patients living with spinal cord injury

~18,000

new cases per annum

8

250,000

new cases per annum

lifetime costs for a 25-year-old quadriplegic patient (US)*** *** Each year ~650 individuals at the age of ~25 become quadriplegic due to spinal cord injury; The Miami Project to Cure Paralysis & SCIMS 2022 Annual Report - Complete Public Version

\$4.8M NO AVAILABLE THERAPEUTIC SOLUTION \$+

* Jain NB, Ayers GD, Peterson EN, et al. Traumatic spinal cord injury in the United States, 1993-2012. JAMA. 2015;313(22):2236-2243

- ** World Health Organization (WHO): https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury

Market size & business model

reimbursement coverage

Autologous engineered neural tissue for spinal cord injury

Roadmap to clinical trials in spinal cord injury patients

Value creating milestones/potential strategic events*

Competitive landscape

current technologies in development for spinal cord injury

			AMEX: LCTX
Attribute	Autologous iPSCs based engineered neural tissue	Adipose derived autologous MSCs	Oligodendrocyte progenitor cells	Collagen scaffold + hUCB-MSCs	iPSCs-derived neural progenitor cells	ESCs derived neural stem cells
Cells
Matrix
Autologous
3D Functioning tissue

Matricelf offers one-of-a-kind functioning, autologous, 3D engineered neural tissue

Competitive advantage

Immune compatibility

The utilization of autologous tissue minimizes the risk of immune response and rejection compared to synthetic or allogeneic alternatives

Functionality

Transplantation of a functional tissue has the potential to unlock a fuller range of capabilities, that individual-cell-based therapies may not achieve

✓ Matricelf is developing technology to 3D-Second platform - early development stage 3D BIOPRINTING

Imagine a world with zero patients in line for organ transplantation

Matricelf's technology can make it happen

• bioprint complex tissues and organs ✓ Based on this technology, a structured human heart was printed in 2019, for the first time, as POC for printing volumetric organs (Noor et al. Adv. Science, 2019) ✓ Multiple potential indications ✓ Potential for JV development program

Corporate & financial details Jan 2024

Management team

ALON SINAI CEO & Co-Founder, board member

TAL BEN NERIAH, MSc VP Operations

SIGAL RUSSO, CPA CFO VP R&D

DORON BIRGER

TAL DVIR, PhD CSO & Co-Founder, board member Chairman

Scientific advisory board

Former senior VP and head of translational sciences at Bayer Pharmaceuticals

Former Executive Director of the Harvard Stem Cell

ADAM WOLLOWICK, MD, USA Orthopedic surgeon; business BROCK REEVE, Mphil, USA Institute

Scientist and stem cell expert at the Ophthalmic Genetics and Visual Function Branch, at NIH

RUCHI SHARMA, PhD, USA NICHOLAS THEODORE, MD, USA Professor of neurosurgery and the director of the Johns Hopkins Neurosurgical Spine Center

MARK TUSZYNSKI, MD PhD, USA Director of the Center for Neural Repair, University of California, San Diego

Why Matricelf?

Pioneering, innovative developer of PERSONALIZED REGENERATIVE THERAPIES, based on proprietary tissue engineering technologies utilizing patients' own tissues and cells

Game-changing platforms for the generation of autologous, complex and volumetric 3D tissues and organs Initial therapeutic target group - paralyzed

Life-changing solutions for large patient groups worldwide

Significant market potential

patients with irreversible spinal cord injury

Value creation events in the short run

Interim readouts during clinical development could provide significant value inflection points or generate strategic events

Thank you

www.matricelf.com